Details of the Drug

General Information of Drug (ID: DMEDSVJ)

Drug Name

Ociperlimab

Synonyms

BGB-A1217

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Cervical cancer	2C77.0	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
V-set and immunoglobulin domain-containing protein 9 (TIGIT)	TTWNL74	TIGIT_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04746924) A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04693234) AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of BeiGene.